Molecular pathways: IL11 as a tumor-promoting cytokine-translational implications for cancers

Clinical Cancer Research

Volumn 20, Issue 22, 2014, Pages 5579-5588

  Ernst, Matthias ^a,b   Putoczki, Tracy L ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; AZD 9150; GLYCOPROTEIN GP 130; INTERLEUKIN 11; INTERLEUKIN 11 MUTEIN; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; JANUS KINASE INHIBITOR; PEPTIDE DERIVATIVE; SILTUXIMAB; STAT3 PROTEIN; TOCILIZUMAB; UNCLASSIFIED DRUG; JANUS KINASE;

ADAPTIVE IMMUNITY; ANEMIA; BREAST TUMOR; CANCER GROWTH; CANCER RESISTANCE; CARCINOGENESIS; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DRUG TARGETING; ENDOMETRIUM CARCINOMA; EPITHELIUM CELL; HUMAN; IMMUNOCOMPETENT CELL; INFECTION; INFLAMMATION; INNATE IMMUNITY; LIVER CANCER; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; NEUTROPENIA; NONHUMAN; PANCREAS CANCER; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; STOMACH TUMOR; THROMBOCYTOPENIA; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR PROMOTION; UTERINE CERVIX CARCINOMA; WOUND HEALING; ANIMAL; CELL TRANSFORMATION; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; TRANSLATIONAL RESEARCH;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CYTOKINE RECEPTOR GP130; HUMANS; INTERLEUKIN-11; JANUS KINASES; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84907865703     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2492     Document Type: Review

References (78)

1. Fearon ER, Vogelstein BA. genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
2. Zang ZJ, Cutcutache I, Poon SL, Zhang SL, McPherson JR, Tao J, et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet 2012;44:570-4.
3. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012;21:309-22.
4. Coussens LM. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 2013;339:286-91.
5. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation and cancer. Cell 2010;140:883-99.
6. Jarnicki A, Putoczki T, Ernst M. STAT3: linking inflammation to epithelial cancer-more than a "gut" feeling? Cell Div 2010;5:14-27.
7. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009;9:798-809.
8. Mantovani A, Allavena P, Balkwill F. Cancer-related inflammation. Nature 2008;457:436-44.
9. Ernst M, Jenkins BJ. Acquiring signalling specificity from the cytokine receptor GP130. Trends Genet 2004;20:23-32.
10. Putoczki T, Ernst M. More than a sidekick: the IL-6 family cytokine IL-11 links inflammation to cancer. J Leukoc Biol 2010;88:1109-17.
11. Cantor SB, Elting LS, Hudson DV Jr, Rubenstein EB. Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy. Cancer 2003;97:3099-106.
12. Robb L, Li R, Hartley L, Nandurkar HH, Koentgen F, Begley CG. Infertility in female mice lacking the receptor for interleukin 11 is due to a defective uterine response to implantation. Nat Med 1998;4:303-8.
13. Matadeen R, Hon WC, Heath JK, Jones EY, Fuller S. The dynamics of signal triggering in a GP130-receptor complex. Structure 2007;15:441-8.
14. Thiem S, Pierce TP, Palmieri M, Putoczki TL, Buchert M, Preaudet, et al. mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice. J Clin Invest 2013;123:767-81.
15. Tebbutt NC, Giraud AS, Inglese M, Jenkins B, Waring P, Clay FJ, et al. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in GP130 mutant mice. Nat Med 2002;8:1089-97.
16. Burdon T, Stracey C, Chambers I, Nichols J, Smith A. Suppression of SHP-2 and ERK signalling promotes self-renewal of mouse embryonic stem cells. Dev Biol 1999;210:30-43.
17. Guo X, Qiu J, Tu T, Yang X, Deng L, Anders RA, et al. Induction of innate lymphoid cell-derived interleukin-22 by the transcription factor STAT3 mediates protection against intestinal infection. Immunity 2014;40:25-39.
18. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, et al. Inhibiting STAT3 signalling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005;11:1314-21.
19. Tsuyada A, Chow A, Wu J, Somlo G, Chu P, Loera S, et al. CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Res 2012;72:2768-79.
20. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118:285-96.
21. Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T, et al. GP130-mediated STAT3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009;15:91-102.
22. Putoczki TL, Thiem S, Loving A, Busuttil RA, Wilson NJ, Ziegler PK, et al. Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell 2013;24:257-71.
23. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, et al. IL-6 and STAT3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009;15:103-13.
24. Huber S, Gagliani N, Zenewicz LA, Huber FJ, Bosurgi L, Hu B, et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 2012;491:259-263.
25. Rigby RJ, Simmons JG, Greenhalgh CJ, Alexander WS, Lund PK. Suppressor of cytokine signalling 3 (SOCS3) limits damage-induced crypt hyper-proliferation and inflammation-associated tumorigenesis in the colon. Oncogene 2007;26:4833-41.
26. Ernst M, Thiem S, Nguyen PM, Eissmann M, Putoczki TL. Epithelial GP130/STAT3 functions: an intestinal signalling node in health and disease. Semin Immunol 2014;26:29-37.
27. Ernst M, Inglese M, Waring P, Campbell IK, Bao S, Clay FJ, et al. Defective GP130-mediated signal transducer and activator of transcription (STAT) signalling results in degenerative joint disease, gastrointestinal ulceration, and failure of uterine implantation. J Exp Med 2001;194:189-203.
28. Cordero JB, Stefanatos RK, Myant K, Vidal M, Sansom OJ. Non-autonomous crosstalk between the Jak/Stat and Egfr pathways mediates Apc1-driven intestinal stem cell hyperplasia in the Drosophila adult midgut. Development 2012;139;4524-35.
29. Schwitalla S, Fingerle AA, Cammareri P, Nebelsiek T, Göktuna SI, Ziegler PK, et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 2013;152:25-38.
30. Huber S, Gagliani N, Zenewicz LA, Huber FJ, Bosurgi L, Hu B, et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 2012;491:259-263.
31. Colonna M. Interleukin-22-producing natural killer cells and lymphoid tissue inducer-like cells in mucosal immunity. Immunity 2009;31:15-23.
32. Hyams JS, Fitzgerald JE, Treem WR, Wyzga N, Kreutzer DL. Relationship of functional and antigenic interleukin 6 to disease activity in inflammatory bowel disease. Gastroenterology 1993;104:1285-92.
33. Atreya R, Mudter J, Finotto S, Müllberg J, Jostock T, Wirtz S, et al. Blockade of interleukin 6 trans signalling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med 2000;6:583-8.
34. Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, Yen HR, et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 2009;15:1016-22.
35. Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B, Jauch D, et al. Adenoma-linked barrier defects and microbial products drive IL- 23/IL-17-mediated tumor growth. Nature 2012;491:254-8.
36. Calon A, Espinet E, Palomo-Ponce S, Tauriello DV, Iglesias M, Céspedes MV, et al. Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. Cancer Cell 2012;22:571-84.
37. Sterling JA, Edwards JR, Martin TJ, Mundy GR. Advances in the biology of bone metastasis: how the skeleton affects tumor behavior. Bone 2011;48:6-15.
38. Bockhorn J, Dalton R, Nwachukwu C, Huang S, Prat A, Yee K, et al. MicroRNA-30c inhibits human breast tumor chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun 2013;4:1393.
39. Meng L, Zhou J, Sasano H, Suzuki T, Zeitoun KM, Bulun SE. Tumor necrosis factor alpha and interleukin 11 secreted by malignant breast epithelial cells inhibit adipocyte differentiation by selectively downregulating CCAAT/enhancer binding protein alpha and peroxisome proliferator-activated receptor gamma: mechanism of desmoplastic reaction. Cancer Res 2001;61:2250-5.
40. Lewis VO, Ozawa MG, Deavers MT, Wang G, Shintani T, Arap W, et al. The interleukin-11 receptor alpha as a candidate ligand-directed target in osteosarcoma: consistent data from cell lines, orthotopic models, and human tumor samples. Cancer Res 2009;69:1995-9.
41. Li TM, Wu CM, Huang HC, Chou PC, Fong YC, Tang CH. Interleukin-11 increases cell motility and up-regulates intercellular adhesion molecule-1 expression in human chondrosarcoma cells. J Cell Biochem 2012;113:3353-62.
42. Sales KJ, Grant V, Cook IH, Maldonado-Pérez D, Anderson RA, Williams AR, at el. Interleukin-11 in endometrial adenocarcinoma is regulated by prostaglandin F2alpha-F-prostanoid receptor interaction via the calcium-calcineurin-nuclear factor of activated T cells pathway and negatively regulated by the regulator of calcineurin-1. Am J Pathol 2010;176:435-45.
43. Lay V, Yap J, Sonderegger S, Dimitriadis E. Interleukin 11 regulates endometrial cancer cell adhesion and migration via STAT3. Int J Oncol 2012;41:759-64.
44. Liu Y, Zhang Y, Fu J, Tan W. Inflammation-related gene expression profiles of endocervical polyps. J Interferon Cytokine Res 2012;32:191-7.
45. Campbell CL, Guardiani R, Ollari C, Nelson BE, Quesenberry PJ, Savarese TM. Interleukin-11 receptor expression in primary ovarian carcinomas. Gynecol Oncol 2001;80:121-7.
46. Furuya Y, Nishio R, Junicho A, Nagakawa O, Fuse H. Serum interleu-kin- 11 in patients with benign prostatic hyperplasia and prostate cancer. Int Urol Nephrol 2005;37:69-71.
47. Campbell CL, Jiang Z, Savarese DM, Savarese TM. Increased expression of the interleukin-11 receptor and evidence of STAT3 activation in prostate carcinoma. Am J Pathol 2001;158:25-32.
48. Zurita AJ, Troncoso P, Cardo-Vila M, Logothetis CJ, Pasqualini R, Arap W. Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer. Cancer Res 2004;64:435-9.
49. Bellone G, Smirne C, Mauri FA, Tonel E, Carbone A, Buffolino A, et al. Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival. Cancer Immunol Immunother 2006;55:684-98.
50. Shin SY, Choi C, Lee HG, Lim Y, Lee YH. Transcriptional regulation of the interleukin-11 gene by oncogenic Ras. Carcinogenesis 2012;33:2467-76.
51. Ernst M, Najdovska M, Grail D, Lundgren-May T, Buchert M, Tye H, et al. STAT3 and STAT1 mediate IL-11-dependent and inflammationassociated gastric tumorigenesis in GP130 receptor mutant mice. J Clin Invest 2008;118:1727-38.
52. Nishina T, Komazawa-Sakon S, Yanaka S, Piao X, Zheng DM, Piao JH, et al. Interleukin-11 links oxidative stress and compensatory proliferation. Sci Signal 2012;5:ra5.
53. Rebouissou S, Amessou M, Couchy G, Poussin K, Imbeaud S, Pilati C, et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumors. Nature 2009;457:200-4.
54. Pilati C, Amessou M, Bihl MP, Balabaud C, Nhieu JT, Paradis V, et al. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J Exp Med 2011;208:1359-66.
55. Yuan JH, Yang F, Wang F, Ma JZ, Guo YJ, Tao QF, et al. A long noncodingRNA activated by TGF-b promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell 2014;25:666-81.
56. Chalaris A, Rabe B, Paliga K, Lange H, Laskay T, Fielding CA, et al. Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signalling function of neutrophils. Blood 2007;110:1748-55.
57. Waldner MJ, Neurath MF. Master regulator of intestinal disease: IL-6 in chronic inflammation and cancer development. Semin Immunol 2014;26:75-79.
58. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005;106:2627-32.
59. Tawara K, Oxford JT, Jorcyk CL. Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies. Cancer Manag Res 2011;3:177-89.
60. Scheller J, Garbers C, Rose-John S. Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities. Semin Immunol 2014;26:2-12.
61. Jackson CB, Judd LM, Menheniott TR, Kronborg I, Dow C, Yeomans ND, et al. Augmented GP130-mediated cytokine signalling accompanies human GC progression. J Pathol 2007;213:140-51.
62. Howlett M, Giraud AS, Lescesen H, Jackson CB, Kalantzis A, Van Driel IR, et al. The interleukin-6 family cytokine interleukin-11 regulates homeostatic epithelial cell turnover and promotes gastric tumor development. Gastroenterology 2009;136:967-77.
63. Tye H, Kennedy CL, Najdovska M, McLeod L, McCormack W, Hughes N, et al. STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell 2012;22:466-78.
64. Kuter DJ. Milestones in understanding platelet production: a historical overview. Br J Haematol 2014;165:248-58.
65. Schumacher D, Strilic B, Sivaraj KK, Wettschureck N, Offermanns S. Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell 2013;24:130-7.
66. Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, Sheehy A, et al. The JAK2 inhibitor AZD1480 potently blocks STAT3 signalling and oncogenesis in solid tumors. Cancer Cell 2009;16:487-97.
67. Constantinescu SN, Girardot M, Pecquet C. Mining for JAK-STAT mutations in cancer. Trends Biochem Sci 2008;33:122-31.
68. Yang LP, Keating GM. Ruxolitinib: in the treatment of myelofibrosis. Drugs 2012;72:2117-27.
69. Stuart E, Buchert M, Putoczki T, Thiem S, Farid R, Elzer J, et al. Therapeutic inhibition of Jak activity inhibits progression of gastrointestinal tumors in mice. Mol Cancer Ther 2014;13:468-74.
70. Xin H, Herrmann A, Reckamp K, Zhang W, Pal S, Hedvat M, et al. Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. Cancer Res 2011;71:6601-10.
71. Ernst M, Phesse TJ, Thiem S, Buchert M. Therapeutic inhibition of GP130/Jak/STAT3-dependent cytokine signalling suppresses WNT-dependent CRC formation. Cytokine 2013;63:261.
72. Hayakawa F, Sugimoto K, Harada Y, Hashimoto N, Ohi N, Kurahashi S, et al. A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases. Blood Cancer J 2013;3:e166.
73. Tangye SG, Cook MC, Fulcher DA. Insights into the role of STAT3 in human lymphocyte differentiation as revealed by the hyper-IgE syndrome. J Immunol 2009;182:21-8.
74. Jenkins BJ, Grail D, Nheu T, Najdovska M, Wang B, Waring P, et al. Hyperactivation of STAT3 in GP130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-beta signalling. Nat Med 2005;11:845-52.
75. Luo J1, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009;136:823-37.
76. Fujishita T, Aoki K, Lane HA, Aoki M, Taketo MM. Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice. Proc Natl Acad Sci U S A 2008;105:13544-49.
77. Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol 2013;10:143-53.
78. Kershaw NJ, Mirphy JM, Liau NPD, Varghese LN, Laktyushin A, Whitlock EL, et al. SOCS3 binds specific receptor-JAK complexes to control cytokine signaling by direct kinase interaction. Nat Struct Mol Biol 2013;20:469-78.